Contineum Therapeutics (CTNM)

• Market cap: $185M
• 1 day: -5.56%
• 5 days: 11.56%
• 1 month: -7.15%
• 3 months: -49.11%
• 6 months: -62.75%
• Year to date: -50.69%
• 1 year: -53.64%
• 5 years: -53.64%
• 10 years: -53.64%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Employees: 41

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

160% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 10

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

20% more funds holding

Funds holding: 51 [Q3] → 61 (+10) [Q4]

11.23% more ownership

Funds ownership: 71.62% [Q3] → 82.85% (+11.23%) [Q4]

10% less capital invested

Capital invested by funds: $256M [Q3] → $231M (-$25.2M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 124% upside
• Avg. target: $24 233% upside
• High target: $31 334% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Debanjana Chatterjee 25% 1-year accuracy 1 / 4 met price target	222% upside $23	Buy Initiated	13 Mar 2025
Morgan Stanley Jeffrey Hung 29% 1-year accuracy 8 / 28 met price target	250% upside $25	Overweight Assumed	7 Mar 2025
Baird Joel Beatty 40% 1-year accuracy 17 / 43 met price target	124% upside $16	Outperform Maintained	7 Mar 2025
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target	334% upside $31	Outperform Reiterated	9 Jan 2025